Article

Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in Huntington’s disease

2021-09-22

Abstract excerpt

<h4>Introduction</h4> Huntington’s disease (HD) is a genetic incurable lethal disease. Biomarkers are needed for objective assessment of disease progression. Evidence supports both complex protein aggregation and astrocyte activation in HD. This study assesses the 42 amino acid long amyloid beta (Aβ42) and glial fibrillary acidic protein (GFAP) as potential biomarkers in the cerebrospinal fluid (CSF) of HD mutati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 52bdc119-c4e3-523e-baa0-14ebc6c2204f
DOI: 10.1101/2021.09.22.461351

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in Huntington’s diseaseDOI 10.1101/2021.09.22.461351Read

Cerebrospinal Fluid Biomarkers for Huntington’s DiseaseSemantic proximity Read

Advances in Huntington’s Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive ReviewSemantic proximity Read

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.Semantic proximity Read

Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patientsSemantic proximity Read

Proteomic profiling of baseline CSF and serum from HDClarity identifies signatures for Huntington disease staging and stratificationSemantic proximity Read

Comparisons of neurodegenerative disease biomarkers across different biological fluids from patients with Huntington’s diseaseSemantic proximity Read

Safety and feasibility of research lumbar puncture in Huntington’s disease: the HDClarity cohort and bioresourceSemantic proximity Read

Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease.Semantic proximity Read

Biomarkers in Huntington's and Parkinson's Disease.Semantic proximity Read

Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.Semantic proximity Read

Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers.Semantic proximity Read

What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington's Disease.Semantic proximity Read